Commonwealth Biotechnologies and New Zealand Pharmaceuticals Enter into Drug Discovery and Development Strategic Alliance

摘要

Commonwealth Biotechnologies (CBI) has entered into a global strategic alliance with New Zealand Pharmaceuticals Ltd (NZP) to provide a suite of small molecule chemistry products for the drug discovery and development market. The alliance will focus on providing glycotherapeutic products and services for research through to process scale-up and commercialization by way of an exclusive referral and co-marketing arrangement. CBI; through its wholly owned subsidiary Exelgen Ltd, will provide customers with research grade products and services, and NZP will supply customers with identified lead candidates for pre-clinical applications through to cGMP products for clinical and therapeutic applications.